

Rajेशha Rupaimoole

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4691655/publications.pdf>

Version: 2024-02-01

62
papers

9,567
citations

71102

41
h-index

114465

63
g-index

63
all docs

63
docs citations

63
times ranked

19124
citing authors

#	ARTICLE	IF	CITATIONS
1	A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells. <i>IScience</i> , 2020, 23, 100878.	4.1	13
2	Pan-cancer genomic analysis links 3â€™UTR DNA methylation with increased gene expression in T cells. <i>EBioMedicine</i> , 2019, 43, 127-137.	6.1	48
3	<i>PRKRA</i> Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 162-172.	4.1	23
4	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018, 78, 3233-3242.	0.9	69
5	Personalized RNA Medicine for Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1734-1747.	7.0	67
6	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018, 9, 2923.	12.8	151
7	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. <i>Oncotarget</i> , 2018, 9, 25115-25126.	1.8	24
8	MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 203-222.	46.4	3,558
9	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	7.0	122
10	Role of Platelet-Derived Tgf β 1 in the Progression of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5611-5621.	7.0	51
11	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	9
12	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017, 8, 310.	12.8	169
13	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. <i>Cell Reports</i> , 2017, 21, 2785-2795.	6.4	32
14	A role for miR-34 in colon cancer stem cell homeostasis. <i>Stem Cell Investigation</i> , 2016, 3, 42-42.	3.0	9
15	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 159-172.	7.3	115
16	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1344-1352.	4.1	41
17	Developing hyperpolarized silicon particles for <i>in vivo</i> MRI targeting of ovarian cancer. <i>Journal of Medical Imaging</i> , 2016, 3, 036001.	1.5	24
18	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016, 7, 11169.	12.8	100

#	ARTICLE	IF	CITATIONS
19	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. <i>Oncogene</i> , 2016, 35, 691-701.	5.9	40
20	Role of Increased n-acetylaspartate Levels in Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv426.	6.3	51
21	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. <i>Cancer Discovery</i> , 2016, 6, 235-246.	9.4	554
22	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. <i>Oncogene</i> , 2016, 35, 4312-4320.	5.9	83
23	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial to Mesenchymal Transition. <i>Journal of Immunology</i> , 2016, 196, 1412-1418.	0.8	66
24	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1713-1724.	7.0	69
25	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. <i>Oncogene</i> , 2016, 35, 2390-2397.	5.9	71
26	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. <i>JCI Insight</i> , 2016, 1, e87754.	5.0	11
27	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	8.2	101
28	Macrophage TGF- β 2 and the Proapoptotic Extracellular Matrix Protein BIGH3 Induce Renal Cell Apoptosis in Prediabetic and Diabetic Conditions. <i>International Journal of Clinical Medicine</i> , 2016, 07, 496-510.	0.2	8
29	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. <i>Npj Systems Biology and Applications</i> , 2015, 1, 15001.	3.0	3
30	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	102
31	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015, 13, 2395-2402.	6.4	105
32	The ZNF304-integrin axis protects against anoikis in cancer. <i>Nature Communications</i> , 2015, 6, 7351.	12.8	48
33	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. <i>Clinical Cancer Research</i> , 2015, 21, 3286-3297.	7.0	37
34	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1466-1475.	4.1	20
35	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015, 28, 610-622.	16.8	94
36	miR-506 inhibits multiple targets in the epithelial to mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. <i>Journal of Pathology</i> , 2015, 235, 25-36.	4.5	94

#	ARTICLE	IF	CITATIONS
37	Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5331-5336.	7.1	79
38	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology, 2014, 10, 728.	7.2	255
39	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell, 2014, 26, 863-879.	16.8	46
40	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2014, 20, 3280-3288.	7.0	80
41	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology and Therapy, 2014, 15, 1061-1067.	3.4	34
42	Cross-talk between EphA2 and BRAF/CRaf Is a Key Determinant of Response to Dasatinib. Clinical Cancer Research, 2014, 20, 1846-1855.	7.0	25
43	Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 1750-1757.	4.1	31
44	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.9	59
45	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications, 2014, 5, 5202.	12.8	151
46	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 2014, 5, 5203.	12.8	195
47	2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	12.8	103
48	Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. Molecular Cancer Therapeutics, 2014, 13, 2876-2885.	4.1	77
49	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell, 2014, 26, 77-91.	16.8	252
50	Autocrine Effects of Tumor-Derived Complement. Cell Reports, 2014, 6, 1085-1095.	6.4	164
51	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	6.4	43
52	Role of Focal Adhesion Kinase in Regulating YAP-Mediated Paclitaxel Resistance in Ovarian Cancer. Journal of the National Cancer Institute, 2013, 105, 1485-1495.	6.3	151
53	Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 2013, 4, 2427.	12.8	363
54	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell, 2013, 23, 186-199.	16.8	340

#	ARTICLE	IF	CITATIONS
55	Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma. <i>Neoplasia</i> , 2013, 15, 502-IN15.	5.3	66
56	A new method for stranded whole transcriptome RNA-seq. <i>Methods</i> , 2013, 63, 126-134.	3.8	59
57	ATP11B mediates platinum resistance in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2119-2130.	8.2	56
58	Complement Component 3 (C3) Is Transcriptionally Regulated By TWIST1. <i>Blood</i> , 2013, 122, 1046-1046.	1.4	1
59	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	27.0	651
60	MicroRNA therapeutics: principles, expectations, and challenges. <i>Chinese Journal of Cancer</i> , 2011, 30, 368-370.	4.9	82
61	MicroRNA therapeutics: principles, expectations, and challenges. <i>Chinese Journal of Cancer</i> , 2011, 30, 368-370.	4.9	1
62	C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells. <i>Matrix Biology</i> , 2009, 28, 347-353.	3.6	19